Vascepa (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovas

Vascepa (icosapent ethyl) 26% Reduction in Key Secondary

Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite E

Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes Study of a Drug Intended to Address Residual Cardiovascular Risk Remaining After Cholesterol

Cardiovascular Death Reduced by 20%

Fatal or Nonfatal Heart Attacks Reduced by 31%

Fatal or Nonfatal Stroke Reduced by 28%

Urgent or Emergent Coronary Revascularization Reduced by 35%

Hospitalization for Unstable Angina Reduced by 32%

Number Needed to Treat for Primary Composite Endpoint: 21

Patient Years of Study Support Favorable Benefit/Risk Profile in REDUCE-IT

Affordably Priced Vascepa Positions Amarin with Potential to Help Millions of Patients

Conference Call Scheduled for Today, Saturday, November 10, 2018 at 7:15 pm CT/8:15 pm ET

CHICAGO, Nov. 10, 2018 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ: AMRN) announced today the primary results from the Vascepa (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT , following presentation of the late-breaking clinical trial results at the 2018

Scientific Sessions of the American Heart Association (AHA) in Chicago, Illinois. REDUCE-IT primary results confirmed 25% relative risk reduction (RRR) for the topline primary endpoint result with multiple

robust demonstrations of efficacy, including 20% reduction in cardiovascular death.

Cardiovascular benefits appeared not to be influenced significantly

by triglyceride (TG) levels at baseline (135 mg/dL to 499 mg/dL baseline range) or as achieved at one year, suggesting mechanisms at work with use of Vascepa that are independent of triglyceride reduction. Results were robust across multiple

subgroups, including in patients with and without diabetes at baseline. REDUCE-IT study results were simultaneously published in The New England Journal of Medicine and are available at

nejm.org/doi/full/10.1056/NEJMoa1812792.

REDUCE-IT was a global study of 8,179 statin-treated adults with

elevated CV risk. Many patients with well-managed LDL-C remain at high risk for cardiovascular events. No therapy is currently approved to treat the residual risk in

REDUCE-IT patients and no other therapy has demonstrated a 25% risk reduction on top of statin therapy in a major cardiovascular outcomes trial. REDUCE-IT studied

Vascepa 4 grams/day as compared to placebo over a median follow-up time of 4.9 years.

Efficacy results for

Vascepa as presented today from REDUCE-IT are as follows:

Primary endpoint achieved: 25% relative risk

reduction (RRR) (hazard ratio (HR), 0.75; 95% confidence interval CI, 0.68-0.83; p<0.001) in first occurrence of major adverse CV events (MACE) in the intent-to-treat population consisting of a composite of cardiovascular death, nonfatal myocardial infarction (MI or heart attack), nonfatal stroke, coronary revascularization (procedures such as stents and by-pass) and unstable angina requiring hospitalization.

Key secondary endpoint

achieved: 26% RRR (HR, 0.74; 95% CI, 0.65-0.83; p<0.001) in 3-point MACE in the

intent-to-treat population consisting of a composite of cardiovascular death, nonfatal heart attack and nonfatal stroke.

Additional secondary endpoints achieved: Seven secondary endpoints were achieved below the key secondary endpoint, as follows (in order of sequential

statistical testing within the prespecified hierarchy):

The next prespecified secondary endpoint in the hierarchy, and the only such endpoint that did not achieve

statistical significance, is as follows:

Baseline demographics:

Patients qualified to enroll in REDUCE-IT had LDL-C between 41-100 mg/dL (median baseline

LDL-C 75 mg/dL) controlled by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides (TGs) between 135-499 mg/dL (median

baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or age 50 or more with diabetes mellitus and at least one other CV risk factor (primary prevention cohort). Approximately 59% of the patients had

diabetes at baseline and approximately 71% of the patients had established cardiovascular disease at time of enrollment.

Safety: Excluding the major

adverse CV events (MACE) results described above, overall adverse event rates in REDUCE-IT were similar across the statin plus Vascepa and the statin plus placebo treatment groups. There were no significant

differences between treatments in the overall rate of treatment emergent adverse events or serious adverse events leading to withdrawal of study drug. The one serious adverse event occurring at a frequency of >2% was pneumonia which occurred at a

numerically higher rate in the statin plus placebo treatment group (2.9%) than in the statin plus Vascepa treatment group (2.6%). Adverse events occurring in 5% or greater of patients and more frequently with Vascepa than placebo were peripheral

edema (6.5% Vascepa patients versus 5.0% placebo patients), constipation (5.4% Vascepa patients versus 3.6% placebo patients), and atrial fibrillation (5.3% Vascepa patients versus 3.9% placebo patients). There were numerically more serious adverse

events related to bleeding in the statin plus Vascepa treatment group although overall rates were low with no fatal bleeding observed in either group and no significant difference in adjudicated hemorrhagic stroke or serious central nervous system

or gastrointestinal bleeding events between treatments. In summary, Vascepa was well tolerated with a safety profile generally consistent with clinical experience associated with omega-3 fatty acids and

current FDA-approved labeling of such products.

REDUCE-IT information: Positive REDUCE-IT results were consistent across various patient subgroups, including female/male,

diabetic/non-diabetic and secondary/primary prevention. At baseline, approximately 59% and 71% of the patients had diabetes and established cardiovascular disease, respectively. Approximately 71% of the

patients studied were classified as Westernized with the largest cohort from the United States. Vital status was obtained for 99.8% of the patients randomized supporting robust trial results.

Differentiated result and mechanism of action: The success of REDUCE-IT is distinct from past failures to show

significant benefit of other agents that lower triglyceride levels when studied on top of statin therapy, including mixtures of omega-3 fatty acids, fenofibrates, niacin and CETP inhibitors. In REDUCE-IT, the median change in triglyceride levels from baseline to year one was -18.3% (-39 mg/dL) for Vascepa and +2.2% (4.5 mg/dL)

for placebo; placebo-corrected median change from baseline of -19.7% (-44.5 mg/dL; p=<0.001). As expressed in The New England Journal of Medicine

publication, at least some of the reduction in MACE demonstrated by Vascepa in REDUCE-IT is likely explained by metabolic effects other than triglyceride lowering.3

The active pharmaceutical ingredient in Vascepa has a unique molecular structure. Vascepa has

demonstrated clinical effects that have not been shown for any other product. The clinical effects of Vascepa demonstrated in REDUCE-IT cannot be generalized to any other product.

Mechanisms responsible for Vascepa s effects in the REDUCE-IT study were not directly evaluated in the outcomes

study. Independent of REDUCE-IT, Amarin has worked to further support the REDUCE-IT hypothesis with published scientific findings based on various degrees of evidence

that show that icosapent ethyl may interrupt the atherosclerotic process (e.g., plaque formation and instability) by beneficially affecting cellular functions thought to contribute to atherosclerosis and cardiovascular events and by beneficially

affecting lipid, lipoprotein and inflammation biomarkers.4, 5, 6, 7, 8

Scientific presentation:

Presentation of the REDUCE-IT results at AHA were made by the Global Principal Investigator and Steering Committee Chair for the study, Deepak L. Bhatt, MD, MPH, Professor of Medicine at Harvard Medical

School, Executive Director of Interventional Cardiovascular Programs at Brigham and Women s Hospital Heart and Vascular Center.

stated, REDUCE-IT establishes a new paradigm for the prevention of important cardiovascular events in statin-treated patients at elevated risk with increased triglycerides. I believe that the results of

this study may represent the most significant breakthrough in preventative cardiovascular care since the introduction of statin therapy decades ago.

Amarin perspective: Commenting on these results from Amarin:

The robustness and consistency of these clinical results are exciting. Extensive scientific evaluation led to the design and conduct of this study; but

the degree of benefit shown with Vascepa nevertheless exceeded our expectation, stated Steven Ketchum, president of research and development and chief scientific officer of Amarin. We believe that these positive results identify an

important new treatment option to help lower cardiovascular risk in appropriate patients. Cholesterol management lowers cardiovascular risk by 25-35%. REDUCE-IT suggests

that the residual 65-75% cardiovascular risk beyond cholesterol management can be significantly lowered with Vascepa in studied patients. We again thank all of the patients, investigators and others involved

in this landmark study.

Amarin has spent over $500 million developing Vascepa. We are intently focused on improving patient care. Our

priorities are now shifting to educate the world regarding these results so that the pain, loss of productivity and high costs of cardiovascular events can be reduced, stated John F. Thero, president and CEO of Amarin.

REDUCE-IT study was designed under a special protocol assessment agreement with the U.S. Food and Drug Administration (FDA). Amarin intends to submit an sNDA to the FDA in early 2019 seeking approval to expand

the label for Vascepa based on the cardioprotective effect of Vascepa demonstrated in the REDUCE-IT study. FDA s determination of standard or priority review will be made when the sNDA is submitted. At

this time, Amarin is planning for a standard review with potential approval anticipated in late 2019.

Vascepa is Affordably Priced

Vascepa is a low-cost drug. The majority of patients covered by insurance who obtain prescriptions for Vascepa pay a

monthly co-pay charge of $9.99 or less. A patient with commercial insurance can pay as little as $9.00 for a 90-day supply prescription of Vascepa.

Commercial Expansion and Next Steps

As previously described, Amarin is in the process of increasing the number of company sales representatives promoting Vascepa to over 400 people in the United

States. Amarin s plans provide for greater concentration of coverage in current sales territories and new coverage where Amarin currently does not have sales representatives. With numerous experienced applicants for these new positions, the

company is well on its way towards having these new sales representatives hired and trained heading into 2019. The company is also planning to support various medical education forums covering preventative solutions in cardiovascular care. Amarin

anticipates making the published results of REDUCE-IT available to healthcare professionals. Following potential label expansion, Amarin will consider other initiatives to expand Vascepa promotion including

more extensive consumer promotion focused on cardiovascular risk reduction.

Financial Disclosure

Funding from Amarin was provided to Brigham and Women s Hospital for Dr. Deepak L. Bhatt s work as the

REDUCE-IT study chair and global principal investigator.

Conference Call and Webcast Information

Amarin will host a conference call at 7:15 p.m. CT/ 8:15 p.m. ET, November 10, 2018 to discuss this information. The call will be accessible through the

investor relations section of the company s website at www.amarincorp.com. The call can also be heard via telephone by dialing 877-407-8033. A replay of the

call will be made available for a period of two weeks following the conference call. To hear a replay of the call, dial 877-481-4010 (inside the United States) or 919-882-2331 (outside the United States). A replay of the call will also be available through the company s website shortly after the call. For both dial-in numbers please use conference ID 39894.

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health.

Amarin s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa (icosapent ethyl) is Amarin s first

FDA-approved drug and is available by prescription in the United States, Lebanon and the United Arab Emirates. Amarin s commercial partners are pursuing additional regulatory approvals for Vascepa in

Canada, China and the Middle East. For more information about Amarin, visit www.amarincorp.com.

About Cardiovascular Disease

Worldwide, cardiovascular disease (CVD) remains the #1 killer of men and women. In the United States CVD leads to one in every three deaths one death

approximately every 38 seconds with annual treatment cost in excess of $500 billion.9, 10

Multiple primary and secondary prevention trials have shown a significant reduction of 25% to 35% in the risk of cardiovascular events with